Glaxo, Novartis, Sanofi, All Cashing In On Swine Flu / H1N1
As the lineups to get H1N1 or swine flu vaccinations grow ever longer it turns out those who supply the drugs for the shots are turning into Big Winners.
Here's how they stack up
GlaxoSmithKline - One of the largest drug companies in the world it is supplying much of the non-USA market and expects its H1N1 sales to top $1.66 Billion. GlaxoSmithKline CEO Andrew Witty says those numbers are...
"pretty close to being right". Similar sales are forecast for the first quarter of 2010.
Some of the other players inlcude;
NOVARTIS which is supplying a big chunk of the US Market expects to rake in around $700 million on the production of about 100 million doses of the H1N1 vaccine.
SANOFI-AVENTIS says it should hit the $500 million mark for sales of the H1N1 vaccine in the USA
BAXTER INTERNATIONAL has a unique cell culture based flu vaccine which should pull in $40 million
ROCHE produces the Tamiflu vaccine often used if the H1N1 is in short supply. It expects to make $2.65 billion in 2009
GlaxoSmithKline the world's second largest drug company by revenue reported an 11 percent rise in its third quarter earnings this week with a net profit of $2.35 billion
Drug companies making big profits adds fuel to the fire of the anti-vaccination movement. If drug companies make huge profits is part of conspiracy then it is a conspiracy that is taking place in full public view.